Valeroyl Salicylate
(Synonyms: 戊酰基水杨酸,2-Valeryloxybenzoic Acid) 目录号 : GC10335
A selective, irreversible inhibitor of COX-1
Cas No.:64206-54-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Valeroyl Salicylate is an irreversible and selective inhibitor of cyclooxygenase-1 (COX-1) with IC50 values of 0.8 and 15 mM for ovine COX-1 and -2, respectively [1].
Cyclooxygenase (COX), also known as prostaglandin-endoperoxide synthase (PTGS, PGHS), is an enzyme responsible for formation of prostanoids, including thromboxane and prostaglandins such as prostacyclin. COX-1 is the constitutive isoform and is mainly responsible for the synthesis of cytoprotective prostaglandins in the gastrointestinal tract (GI) and of the proaggregatory thromboxane in blood platelets. COX-2 is inducible and short-lived that is stimulated by endotoxin, cytokines, and mitogens. COX-2 plays important roles in prostaglandin biosynthesis in inflammatory cells the central nervous system [1][2].
Valeroyl Salicylate is an irreversible and selective inhibitor of cyclooxygenase-1 (COX-1) with IC50 values of 0.8 and 15 mM for ovine COX-1 and -2, respectively. In cos-1 cells expressing either COX-1 or -2, 500 μM of valeroyl salicylate inhibited human COX-1 and -2 by 85% and 15%, respectively. The half-lives for inactivation of human recombinant COX-1 in the presence of 500 μM valeroyl salicylate was 12 minutes [2].
References:
[1]. Johnson JL, Wimsatt J, Buckel SD, et al. Purification and characterization of prostaglandin H synthase-2 from sheep placental cotyledons. Arch Biochem Biophys. 1995 Dec 1;324(1):26-34.
[2]. Bhattacharyya DK, Lecomte M, Dunn J, et al. Selective inhibition of prostaglandin endoperoxide synthase-1 (cyclooxygenase-1) by valerylsalicylic acid. Arch Biochem Biophys. 1995 Feb 20;317(1):19-24.
| Cas No. | 64206-54-8 | SDF | |
| 别名 | 戊酰基水杨酸,2-Valeryloxybenzoic Acid | ||
| 化学名 | 2-[(1-oxopentyl)oxy]-benzoic acid | ||
| Canonical SMILES | CCCCC(=O)Oc1ccccc1C(=O)O | ||
| 分子式 | C12H14O4 | 分子量 | 222.2 |
| 溶解度 | ≥ 14.15mg/mL in DMSO | 储存条件 | Room temperature |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.5005 mL | 22.5023 mL | 45.0045 mL |
| 5 mM | 0.9001 mL | 4.5005 mL | 9.0009 mL |
| 10 mM | 0.45 mL | 2.2502 mL | 4.5005 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。